Revenue

3 Months Ended

Dec. 31, 2022

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended December 31,
(In thousands)	2022		2021
Medical Device
Product sales	$	8,380	$	6,788
Royalties		7,409		6,886
License fees		1,356		1,213
Research, development and other		1,873		2,021
Medical Device Revenue		19,018		16,908
In Vitro Diagnostics
Product sales		5,854		5,556
Research, development and other		61		539
In Vitro Diagnostics Revenue		5,915		6,095
Total Revenue	$	24,933	$	23,003

Contract assets totaled $7.0 million and $7.1 million as of December 31, 2022 and September 30, 2022, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.